BIIB Longer Swing Setup

BIIB SWING NOTE  ·  SEPTEMBER 27, 2026

Why the short trade is thin, and where the 6 to 12 week setup lives

Friday, September 25 close $227.60  ·  52-week high $229.19  ·  Earnings October 29, 2026

Biogen (NASDAQ: BIIB) is coiled under a three-day rejection of its 52-week high at $229.19. The weekly trend is still up. That is why the name keeps showing up on near-breakout scans. It is also why a 3- to 15-day scalp from here does not pay enough.

This is a longer swing framework, about 6 to 12 weeks: location first, a defined stop, two scale targets, and a hard invalidation. It is not a recommendation to buy or sell BIIB.

Why the short-term sheet looked weak

From Friday’s close you are already on the 52-week high shelf. Consensus targets cluster near $230. Daily oscillators are stretched. Friday volume was below the 65-day average. First short-term targets are only about +3% to +7%, and a responsible stop is already about 3%.

That is a scalp. It is not a swing. A longer hold only makes sense if you give the stock room through the October 29 earnings report and aim at the next real supply zone, not the $229 print.

The 6 to 12 week thesis

Price is above the 50-day near $213 and the 200-day near $194. The measured magnet from the summer uptrend channel is $238, then $258. That $258 area is old 2023 / 2024 supply and the first level that actually changes the quarterly P&L.

The calendar overlay is simple:

• Q3 earnings, expected before the open on October 29, 2026.
• Litifilimab Phase 3 SLE readouts (TOPAZ-1 and TOPAZ-2) expected by year-end 2026.
• Leqembi subcutaneous initiation is already in market in the U.S., with more geographic approvals in 2026. That is the growth product, not a fresh binary FDA date from here.

Historical actual earnings moves in BIIB have often landed near 3% to 4%, while options sometimes price closer to 5%. On a 12-week trade that gap is noise. On a 5-day trade it is the whole trade.

What changes versus the short plan

• The stop lives under weekly structure, not Friday’s low.
• First scale is $238, not $229.
• Main target is $258. Stretch is $275 to $280.
• You accept an earnings gap unless the print is a clean miss that closes the week back under $213.

Map of the tape

Scroll right on a phone to read the full row.

Zone	Price	Why it matters
Breakout / add	$229.20 – $232.00	52-week high $229.19 plus Friday high $228.92. A weekly close through $232 is the only clean buy-the-high.
Current coil	$226.00 – $228.00	Last three-day balance. Worst location to start a 12-week position.
20-day pullback	$218.50 – $219.50	Preferred first dip if the high test is only a pause.
50-day pullback	$212.50 – $214.50	September 21 low $214.59. Best longer-swing location on the sheet.
Weekly invalidation	$204.00 – $205.00	Loss of the 100-day / rising intermediate trend. Weekly close under here ends the idea.
First scale	$238	Daily measured move / summer-channel first target.
Main target	$258	Prior multi-month supply. This is the actual swing objective.
Stretch	$275 – $280	Runner only, trailed under the 10-week average.

Longer swing table

Returns are from the planned entry, not from Friday’s $227.60. Probabilities are conditional on the setup triggering. They are judgment from this structure, not a backtest.

This sheet is 12 columns. Scroll right to see stretch targets and probabilities. Nothing wraps.

Setup	Entry	Stop	Exit 1	Return 1	Exit 2	Return 2	Stretch	Stretch %	P(Exit 1)	P(Exit 2)	P(stop)
Buy the high	$227.60	$204.50	$238	+4.6%	$258	+13.4%	$278	+22.1%	45%	28%	35%
20-day pullback	$219.00	$204.50	$238	+8.7%	$258	+17.8%	$278	+26.9%	52%	32%	30%
50-day pullback	$213.50	$198.00	$238	+11.5%	$258	+20.8%	$278	+30.2%	50%	34%	32%
Breakout add	$232.00	$212.50	$248	+6.9%	$258	+11.2%	$278	+19.8%	40%	30%	38%

Why row 1 is still only average. From $227.60, risk to $204.50 is about −10.1%. Reward to $258 is about +13.4%. That is roughly 1.3R. The pullback rows are the actual swing: risk about 7% to 9%, reward about 18% to 21%, closer to 2R. If you cannot wait for $213 to $219, you do not have a longer swing. You have the short trade with a wider stop.

How to run it

1. Do not start a 12-week position at $227 to $229 unless BIIB closes a week above $229.19 on rising volume. That is the only version of buy-the-high that is not lazy.
2. Preferred book: wait for $213 to $219, risk $198 to $204.50, target $258, time stop at year-end or two sessions after the SLE readout if it prints earlier.
3. Scale 30% at $238, 40% at $258, and leave 30% as a runner toward $275 to $280 with a trail under the 10-week average.
4. Kill the idea on a weekly close under $204 to $205. Daily noise through $221 does not count.
5. If October 29 is a clean miss and the stock closes back under $213, flatten. A routine beat or guidance hold and a dip is a buy for this timeframe.
6. Position size off the dollar distance to the stop, not off conviction. A liquid $34 billion name still gaps.

What would make this not worth doing

• A weekly close under $204.50 before you are filled on a pullback. Then wait for a new base.
• A failed weekly breakout: spike through $232 on light volume and a close back under $226. That is a fade for a short-term trader, not an add for a longer swing.
• Starting size at $227.60 because the scanner said near breakout. Location is the edge. The label is not.

Bottom line: the short table looked weak because it is weak at this price. The longer swing is only worth the hold on a dip to $213 to $219, or on a weekly close through $232. Chasing $227 for +4.6% into $238 is not a longer swing.

Disclaimer

This post is for information and education only. It is not investment advice, tax advice, legal advice, or a solicitation to buy or sell any security, option, or other instrument. Nothing here is a recommendation that you take any of the setups.

Biogen Inc. (BIIB) is used as a worked example of swing-trade planning. Prices, moving averages, earnings dates, volume figures, and catalyst timing were assembled from public market data as of the September 25, 2026 cash close and from publicly reported company and news sources as of September 27, 2026. All of those inputs can change. Levels can be printed and reversed in a single session.

The percentages are arithmetic moves from a stated entry to a stated exit. They are not expected returns, not compound returns, and not net of commissions, slippage, borrow, or taxes. Stops can gap through. Earnings gaps can open beyond both the target and the stop.

The probabilities are subjective estimates of how this tape has often behaved in similar conditions. They are not statistical forecasts, not implied-volatility probabilities, and not a backtest. They will be wrong some of the time. Past performance is not a reliable guide to future results.

Trading stocks and holding through earnings involves a risk of loss, including loss of principal. Size positions so that a full stop-out is acceptable. Do your own work. Consider talking with a licensed adviser who knows your facts before you place a trade. No position disclosure is implied. The author may or may not hold BIIB or related options at any time. This page is not updated automatically when the quote changes.